OBJECTIVE: Enthesitis-related arthritis (ERA) is an inflammatory disease of childhood that lacks autoantibodies. Overexpression of surface-expressed Toll-like receptors (TLRs) has been found in ERA. Myeloid-related proteins (MRPs) 8 and 14 are calcium binding proteins that act as an endogenous ligand of TLR4. MRP8/14 levels are elevated in patients with systemic-onset arthritis. Thus we studied the role of MRP8/14 in ERA. METHODS: The study enrolled patients with ERA. Plasma and SF levels of MRP8/14 were measured by ELISA and TLR4 expression on peripheral blood and SF monocytes was measured by two-colour flow cytometry. Control plasma samples were collected from 48 blood bank donors. RESULTS: Of the 69 patients, 67 were male, with a mean age of 15.2 (s.d. 2.7) years and a disease duration of 5 (s.d. 3) years. Median plasma levels of MRP8/14 were higher in patients (10 862.3 ng/ml) than controls (4426.1 ng/ml, P < 0.0001). Patients with active disease (11 669.5 ng/ml) had higher levels as compared with inactive disease (4421.8 ng/ml, P < 0.0001). Plasma MRP8/14 levels decreased on follow-up after 3 months only in patients who responded to treatment (P = 0.012). MRP8/14 levels were negatively correlated with the frequency of CD14(+)TLR4(+) cells (r = -0.372, P = 0.02). MRP8/14 levels were higher in SF as compared with plasma (15 858.45 ng/ml, P = 0.024). The frequency of CD14(+)TLR4(+) cells was higher in SF as compared with peripheral blood. CONCLUSION: MRP8/14 levels are increased in the plasma of ERA patients and are higher in those with active disease and the levels decrease in patients who respond to treatment, suggesting that it may be a good biomarker during follow-up.
OBJECTIVE: Enthesitis-related arthritis (ERA) is an inflammatory disease of childhood that lacks autoantibodies. Overexpression of surface-expressed Toll-like receptors (TLRs) has been found in ERA. Myeloid-related proteins (MRPs) 8 and 14 are calcium binding proteins that act as an endogenous ligand of TLR4. MRP8/14 levels are elevated in patients with systemic-onset arthritis. Thus we studied the role of MRP8/14 in ERA. METHODS: The study enrolled patients with ERA. Plasma and SF levels of MRP8/14 were measured by ELISA and TLR4 expression on peripheral blood and SF monocytes was measured by two-colour flow cytometry. Control plasma samples were collected from 48 blood bank donors. RESULTS: Of the 69 patients, 67 were male, with a mean age of 15.2 (s.d. 2.7) years and a disease duration of 5 (s.d. 3) years. Median plasma levels of MRP8/14 were higher in patients (10 862.3 ng/ml) than controls (4426.1 ng/ml, P < 0.0001). Patients with active disease (11 669.5 ng/ml) had higher levels as compared with inactive disease (4421.8 ng/ml, P < 0.0001). Plasma MRP8/14 levels decreased on follow-up after 3 months only in patients who responded to treatment (P = 0.012). MRP8/14 levels were negatively correlated with the frequency of CD14(+)TLR4(+) cells (r = -0.372, P = 0.02). MRP8/14 levels were higher in SF as compared with plasma (15 858.45 ng/ml, P = 0.024). The frequency of CD14(+)TLR4(+) cells was higher in SF as compared with peripheral blood. CONCLUSION:MRP8/14 levels are increased in the plasma of ERA patients and are higher in those with active disease and the levels decrease in patients who respond to treatment, suggesting that it may be a good biomarker during follow-up.
Authors: Beverly R E A Dixon; Tiffany J Lee; Diana C Contreras Healey; Jing Li; Jeremy A Goettel; M Blanca Piazuelo; Holly M Scott Algood Journal: Immunohorizons Date: 2022-02-10
Authors: Faekah Gohar; Janneke Anink; Halima Moncrieffe; Lisette W A Van Suijlekom-Smit; Femke H M Prince; Marion A J van Rossum; Koert M Dolman; Esther P A H Hoppenreijs; Rebecca Ten Cate; Simona Ursu; Lucy R Wedderburn; Gerd Horneff; Michael Frosch; Dirk Foell; Dirk Holzinger Journal: J Rheumatol Date: 2018-01-15 Impact factor: 4.666
Authors: Beverly R E A Dixon; Jana N Radin; M Blanca Piazuelo; Diana C Contreras; Holly M Scott Algood Journal: PLoS One Date: 2016-02-11 Impact factor: 3.240
Authors: Janneke Anink; Lisette W A Van Suijlekom-Smit; Marieke H Otten; Femke H M Prince; Marion A J van Rossum; Koert M Dolman; Esther P A H Hoppenreijs; Rebecca ten Cate; Simona Ursu; Lucy R Wedderburn; Gerd Horneff; Michael Frosch; Thomas Vogl; Faekah Gohar; Dirk Foell; Johannes Roth; Dirk Holzinger Journal: Arthritis Res Ther Date: 2015-08-07 Impact factor: 5.156